Loading...
Products:Cell Biology >> Cell Cycle >> Cell Cycle Inhibitors >> Other
If your product does not perform as described on this datasheet, we will refund or replace your product...
Read our guarantee »Tuberin peptide
See all Tuberin products (4) ...
15 amino acid synthetic peptide from near the C terminus of Human Tuberin.
Liquid
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Preservative: 0.02% Sodium Azide
Constituents: 0.1% BSA, PBS, pH 7.2
Concentration information loading...
Metabolism >> Types of disease >> Obesity
Epigenetics and Nuclear Signaling >> Transcription >> Cancer susceptibility >> Tumor Suppressors
Signal Transduction >> Protein Trafficking >> Vesicle Transport >> Regulation
Cell Biology >> Cell Cycle >> Cell Cycle Inhibitors >> Other
Our Abpromise guarantee covers the use of ab39898 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
BL: Use at an assay dependent dilution.
WB: Use at an assay dependent dilution. Predicted molecular weight: 200 kDa.
Tuberin peptide is used for blocking the activity of the Tuberin antibody ab25883. It usually blocks the antibody activity completely in Western blot by incubating the peptide with equal volume of antibody for 30 min at 37°C.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
In complex with TSC1, inhibits the nutrient-mediated or growth factor-stimulated phosphorylation of S6K1 and EIF4EBP1 by negatively regulating mTORC1 signaling. Acts as a GTPase-activating protein (GAP) for the small GTPase RHEB, a direct activator of the protein kinase activity of mTORC1. Implicated as a tumor suppressor. Involved in microtubule-mediated protein transport, but this seems to be due to unregulated mTOR signaling. Stimulates weakly the intrinsic GTPase activity of the Ras-related proteins RAP1A and RAB5 in vitro. Mutations in TSC2 lead to constitutive activation of RAP1A in tumors.
Liver, brain, heart, lymphocytes, fibroblasts, biliary epithelium, pancreas, skeletal muscle, kidney, lung and placenta.
Defects in TSC2 are the cause of tuberous sclerosis type 2 (TSC2) [MIM:613254]. TSC2 is an autosomal dominant multi-system disorder that affects especially the brain, kidneys, heart, and skin. It is characterized by hamartomas (benign overgrowths predominantly of a cell or tissue type that occurs normally in the organ) and hamartias (developmental abnormalities of tissue combination). Clinical symptoms can range from benign hypopigmented macules of the skin to profound mental retardation with intractable seizures to premature death from a variety of disease-associated causes.
Defects in TSC2 are a cause of lymphangioleiomyomatosis (LAM) [MIM:606690]. LAM is a progressive and often fatal lung disease characterized by a diffuse proliferation of abnormal smooth muscle cells in the lungs. It affects almost exclusively young women and can occur as an isolated disorder or in association with tuberous sclerosis complex.
Contains 1 Rap-GAP domain.
Phosphorylation at Ser-1387, Ser-1418 or Ser-1420 does not affect interaction with TSC1.
Phosphorylation at Ser-939 and Thr-1462 by PKB/AKT1 is induced by growth factor stimulation.
Cytoplasm. Membrane. At steady state found in association with membranes.
Target information above from: UniProt accessionP49815
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).
ab39898 has not yet been referenced specifically in any publications.
Publishing research using ab39898? Please let us know so that we can cite the reference in this datasheet
Concentration of lot no. is
Concentration not available for this lot.
Find concentration of your lot:
0
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
Call 01223 696 000 or contact us
